000147114 001__ 147114
000147114 005__ 20241212141912.0
000147114 0247_ $$2doi$$a10.1038/s41541-024-01009-5
000147114 0248_ $$2sideral$$a140970
000147114 037__ $$aART-2024-140970
000147114 041__ $$aeng
000147114 100__ $$aPeralta-Álvarez, Marco Polo
000147114 245__ $$aMTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates
000147114 260__ $$c2024
000147114 5060_ $$aAccess copy available to the general public$$fUnrestricted
000147114 5203_ $$aThe only currently licensed vaccine against tuberculosis (TB), Bacille Calmette Guérin (BCG), is insufficient to control the epidemic. MTBVAC is a live attenuated strain of Mycobacterium tuberculosis (M.tb) and is one the most advanced TB vaccine candidates in the pipeline. It is more efficacious than BCG in preclinical models including non-human primates (NHPs), and has demonstrated safety and immunogenicity in human populations. To better understand the immune mechanisms underlying the superior efficacy conferred by MTBVAC, we characterized M.tb-specific antibody responses in NHPs vaccinated with either BCG or MTBVAC. MTBVAC vaccination induced higher titers of IgG, IgM and IgA, and higher avidity IgG compared with BCG vaccination. IgG avidity correlated with protection following M.tb challenge in the same animals, validating the association previously reported between this measure and protection in the context of intravenous BCG vaccination, suggesting that IgG avidity may represent a relevant marker or correlate of protection from TB.
000147114 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000147114 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000147114 700__ $$aDownward, Keya
000147114 700__ $$aWhite, Andrew
000147114 700__ $$aRedondo Azema, Hugo
000147114 700__ $$aSibley, Laura
000147114 700__ $$aSarfas, Charlotte
000147114 700__ $$aMorrison, Alexandra
000147114 700__ $$aDennis, Mike
000147114 700__ $$aDiaz-Santana, Delia
000147114 700__ $$aHarris, Stephanie A.
000147114 700__ $$aLi, Shuailin
000147114 700__ $$aPuentes, Eugenia
000147114 700__ $$0(orcid)0000-0001-7897-9173$$aAguilo, Nacho$$uUniversidad de Zaragoza
000147114 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, Carlos$$uUniversidad de Zaragoza
000147114 700__ $$aSharpe, Sally
000147114 700__ $$aMcShane, Helen
000147114 700__ $$aTanner, Rachel
000147114 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000147114 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000147114 773__ $$g9, 1 (2024), 10 pp.$$pnpj Vaccines$$tnpj Vaccines$$x2059-0105
000147114 8564_ $$s1774531$$uhttps://zaguan.unizar.es/record/147114/files/texto_completo.pdf$$yVersión publicada
000147114 8564_ $$s2903724$$uhttps://zaguan.unizar.es/record/147114/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000147114 909CO $$ooai:zaguan.unizar.es:147114$$particulos$$pdriver
000147114 951__ $$a2024-12-12-12:43:13
000147114 980__ $$aARTICLE